MY138059A - Use of ikb-kinase inhibitors in pain therapy - Google Patents

Use of ikb-kinase inhibitors in pain therapy

Info

Publication number
MY138059A
MY138059A MYPI20033112A MYPI20033112A MY138059A MY 138059 A MY138059 A MY 138059A MY PI20033112 A MYPI20033112 A MY PI20033112A MY PI20033112 A MYPI20033112 A MY PI20033112A MY 138059 A MY138059 A MY 138059A
Authority
MY
Malaysia
Prior art keywords
ikb
kinase inhibitors
pain therapy
inhibitors
pain
Prior art date
Application number
MYPI20033112A
Inventor
Martin Dr Michaelis
Olaf Dr Ritzeler
Gerhard Dr Jaehne
Karl Dr Rudolphi
Gerd Prof Geisslinger
Hans-Georg Prof Schaible
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MY138059A publication Critical patent/MY138059A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

IkB-KINASE INHIBITORS ARE SUITABLE FOR THE PREPARATION OF PHARMACEUTICALS FOR TREATING PAINS. SUITABLE INHIBITORS ARE COMPOUNDS OF THE FORMULA I AND IA.
MYPI20033112A 2002-08-17 2003-08-15 Use of ikb-kinase inhibitors in pain therapy MY138059A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (en) 2002-08-17 2002-08-17 Use of IKappaB kinase inhibitors in pain therapy

Publications (1)

Publication Number Publication Date
MY138059A true MY138059A (en) 2009-04-30

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20033112A MY138059A (en) 2002-08-17 2003-08-15 Use of ikb-kinase inhibitors in pain therapy

Country Status (33)

Country Link
EP (1) EP1531819B1 (en)
JP (1) JP4504811B2 (en)
KR (2) KR101119845B1 (en)
CN (1) CN100398107C (en)
AR (1) AR043045A1 (en)
AT (1) ATE418336T1 (en)
AU (1) AU2003271555B2 (en)
BR (1) BR0313555A (en)
CA (1) CA2495455C (en)
CO (1) CO5690585A2 (en)
CR (1) CR7716A (en)
CY (1) CY1108874T1 (en)
DE (2) DE10237723A1 (en)
DK (1) DK1531819T3 (en)
EC (1) ECSP055609A (en)
ES (1) ES2320118T3 (en)
HR (1) HRP20050041B1 (en)
IL (1) IL166780A (en)
MA (1) MA27334A1 (en)
MX (1) MXPA05001218A (en)
MY (1) MY138059A (en)
NO (1) NO334309B1 (en)
OA (1) OA12907A (en)
PL (1) PL212356B1 (en)
PT (1) PT1531819E (en)
RS (1) RS51878B (en)
RU (1) RU2320338C2 (en)
SI (1) SI1531819T1 (en)
TN (1) TNSN05044A1 (en)
TW (1) TWI325782B (en)
UA (1) UA80837C2 (en)
WO (1) WO2004022057A1 (en)
ZA (1) ZA200500323B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7312044B2 (en) 2003-03-07 2007-12-25 The Trustees Of Columbia University In The City Of New York Type 1 ryanodine receptor-based methods
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EA200700243A1 (en) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. METHODS OF TREATMENT OF HEPATITIS C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
DE102005025225A1 (en) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Process for the preparation of 2- (2-amino-pyrimidin-4-yl) -1H-indole-5-carboxylic acid derivatives
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
AR072297A1 (en) 2008-06-27 2010-08-18 Novartis Ag DERIVATIVES OF INDOL-2-IL-PIRIDIN-3-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE SYNTHESIS ALDOSTERONE.
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201242962A (en) 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (en) 2011-03-08 2014-12-17 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
DK2787998T3 (en) * 2011-12-06 2017-02-06 Sanofi Sa Crystalline Forms of 2- (2-METHYLAMINOPYRIMIDIN-4-YL) -1H-INDOL-5-CARBOXYLIC ACID - [(S) -1-CARBAMOYL-2- (PHENYLPYRIMIDIN-2-YLAMINO) -ETHYL] -AMIDE
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (en) * 2013-07-15 2019-10-20 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors
SG11201610429YA (en) * 2014-07-03 2017-01-27 Sanofi Sa 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide for use in the treatment of pain associated to osteoarthritis
AU2019304216B2 (en) 2018-07-16 2022-06-02 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1047582B (en) * 1999-06-23 2005-03-04 萨诺费－阿文蒂斯德国有限公司 Substituted benzimidazole
DE19951360A1 (en) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituted indoles
DE10237722A1 (en) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase

Also Published As

Publication number Publication date
IL166780A (en) 2011-11-30
WO2004022057A1 (en) 2004-03-18
HK1079426A1 (en) 2006-04-07
KR101119845B1 (en) 2012-02-28
DK1531819T3 (en) 2009-04-20
CO5690585A2 (en) 2006-10-31
RU2320338C2 (en) 2008-03-27
AU2003271555A1 (en) 2004-03-29
CN100398107C (en) 2008-07-02
JP2005539053A (en) 2005-12-22
NO334309B1 (en) 2014-02-03
CA2495455C (en) 2011-01-11
ZA200500323B (en) 2006-02-22
UA80837C2 (en) 2007-11-12
KR20110135428A (en) 2011-12-16
MA27334A1 (en) 2005-05-02
DE50310980D1 (en) 2009-02-05
AR043045A1 (en) 2005-07-13
MXPA05001218A (en) 2005-05-16
PT1531819E (en) 2009-02-18
TNSN05044A1 (en) 2007-05-14
TWI325782B (en) 2010-06-11
PL373568A1 (en) 2005-09-05
AU2003271555B2 (en) 2009-03-26
NO20051339L (en) 2005-05-03
CA2495455A1 (en) 2004-03-18
TW200417370A (en) 2004-09-16
EP1531819A1 (en) 2005-05-25
ATE418336T1 (en) 2009-01-15
ECSP055609A (en) 2005-04-18
HRP20050041A2 (en) 2006-04-30
KR20050058339A (en) 2005-06-16
PL212356B1 (en) 2012-09-28
DE10237723A1 (en) 2004-07-08
RS20050070A (en) 2007-06-04
SI1531819T1 (en) 2009-06-30
RU2005107419A (en) 2005-08-10
ES2320118T3 (en) 2009-05-19
RS51878B (en) 2012-02-29
EP1531819B1 (en) 2008-12-24
IL166780A0 (en) 2006-01-15
OA12907A (en) 2006-10-13
CY1108874T1 (en) 2014-07-02
JP4504811B2 (en) 2010-07-14
BR0313555A (en) 2005-07-12
CR7716A (en) 2008-11-25
CN1674899A (en) 2005-09-28
HRP20050041B1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
AU2003300791A1 (en) Combination therapy for the treatment of pain
TR200200204T2 (en) Treating chronic pain using MEK inhibitors.
EA200501849A1 (en) DERIVATIVES OF PYRAZOLOHINAZOLINE: METHOD FOR OBTAINING AND USING AS KINAZ INHIBITORS
IL164599A0 (en) Combination therapy for the treatment of cancer
MY151032A (en) Treatment of tnf? related disorders
SG145700A1 (en) Pyridyl derivatives and their use as therapeutic agents
SG145695A1 (en) Pyridyl derivatives and their use as therapeutic agents
CY1109229T1 (en) USE OF SPOGGOSIN (2-Methoxyadenosine) For Pain Therapy, Specific Subconscious Pain
MXPA05005223A (en) Diaminotriazoles useful as inhibitors of protein kinases.
MY136037A (en) Biphenyl pyrimidone lp-pla2 inhibitors
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
ZA200108413B (en) Use of glycosyceramide synthesis inhibitors in therapy.
GB0222514D0 (en) Organic compounds
SI1758860T1 (en) Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in the treatment of pains, depressions and anxiety states
SE9802208D0 (en) Novel compounds
MXPA04004372A (en) Heterocyclic derivatives of glycinamide and their medical use.
DK1689404T3 (en) Combination of et-743 with 5-fluoracil prodrugs for the treatment of cancer
TW200508233A (en) Chk-1 inhibitors
AU2001246600A1 (en) Use of comt inhibitors as analgesics
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
SI1545710T1 (en) USE OF N-(3-METHOXY-5-METHYLPYRAZIN-2-YL)-2-(4-?á1,3,4-OXADIAZOL-2-YL?åPHENYL)PYRIDINE-3-SULPHONAMIDE IN THE TREATMENT OF CANCER
SE9802209D0 (en) Novel compounds
MXPA06007007A (en) Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours.